202 related articles for article (PubMed ID: 33978973)
21. Successful prolonged treatment of glecaprevir/pibrentasvir for chronic hepatitis C patient with treatment failure after 8-week therapy: a case report.
Naganuma A; Sato K; Fukuchi T; Namikawa M; Kakizaki S; Uraoka T; Ohnishi H; Okamoto H
Clin J Gastroenterol; 2019 Dec; 12(6):592-597. PubMed ID: 31376076
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea.
Shin HD; Song IH; Lee SH; Kim HS; Lee TH; Eun HS; Kim SH; Lee BS; Chae HB; Kim SH; Song MJ; Ko SY; Kim SB
Korean J Gastroenterol; 2024 Mar; 83(3):111-118. PubMed ID: 38522854
[TBL] [Abstract][Full Text] [Related]
23. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections.
Sezaki H; Suzuki F; Hosaka T; Fujiyama S; Kawamura Y; Akuta N; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Gastroenterol; 2019 Oct; 54(10):916-927. PubMed ID: 30903385
[TBL] [Abstract][Full Text] [Related]
24. Changes in Alcohol Consumption following Direct-Acting Antiviral Treatment for Hepatitis C in VA Patients with Comorbid Alcohol Use Disorder and PTSD.
Hoyt JE; Teja N; Jiang T; Rozema L; Gui J; Watts BV; Shiner B; Gradus JL
J Dual Diagn; 2022; 18(4):185-198. PubMed ID: 36151743
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination: Real-world experience of a retrospective study.
Li J; Wu DB; Jiang W; Chen XB; Xiao GB; Wang YH; Wang ML; Tao YC; Chen EQ
Medicine (Baltimore); 2020 Oct; 99(43):e22726. PubMed ID: 33120769
[TBL] [Abstract][Full Text] [Related]
26. Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy.
Smith DA; Bradshaw D; Mbisa JL; Manso CF; Bibby DF; Singer JB; Thomson EC; da Silva Filipe A; Aranday-Cortes E; Ansari MA; Brown A; Hudson E; Benselin J; Healy B; Troke P; McLauchlan J; Barnes E; Irving WL
J Viral Hepat; 2021 Sep; 28(9):1256-1264. PubMed ID: 34003556
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
[TBL] [Abstract][Full Text] [Related]
28. Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir.
Nguyen E; Trinh S; Trinh H; Nguyen H; Nguyen K; Do A; Levitt B; Do S; Nguyen M; Purohit T; Shieh E; Nguyen MH
Aliment Pharmacol Ther; 2019 Jan; 49(1):99-106. PubMed ID: 30467877
[TBL] [Abstract][Full Text] [Related]
29. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients.
Agarwal K; Castells L; Müllhaupt B; Rosenberg WMC; McNabb B; Arterburn S; Camus G; McNally J; Stamm LM; Brainard DM; Mani Subramanian G; Mariño Z; Dufour JF; Forns X
J Hepatol; 2018 Sep; 69(3):603-607. PubMed ID: 29886154
[TBL] [Abstract][Full Text] [Related]
30. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment.
Liu CH; Yang SS; Peng CY; Lin WT; Liu CJ; Su TH; Tseng TC; Chen PJ; Chen DS; Kao JH
J Viral Hepat; 2020 Jun; 27(6):568-575. PubMed ID: 31981264
[TBL] [Abstract][Full Text] [Related]
31. The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis.
Chen R; Xiong Y; Zeng Y; Wang X; Xiao Y; Zheng Y
Front Public Health; 2023; 11():1179531. PubMed ID: 37841743
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study.
Wu DB; Jiang W; Wang YH; Chen B; Wang ML; Tao YC; Chen EQ; Tang H
J Viral Hepat; 2019 Mar; 26(3):316-322. PubMed ID: 30380166
[TBL] [Abstract][Full Text] [Related]
33. Concomitant use of direct-acting antivirals (DAA) and central nervous system drugs in patients with hepatitis C virus infection.
Sicras-Mainar A; Morillo-Verdugo R
Adicciones; 2022 Nov; 34(4):279-284. PubMed ID: 33338248
[TBL] [Abstract][Full Text] [Related]
34. Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics.
Kim NG; Kullar R; Khalil H; Saab S
J Viral Hepat; 2020 Aug; 27(8):762-769. PubMed ID: 32386099
[TBL] [Abstract][Full Text] [Related]
35. Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure.
Graf C; D'Ambrosio R; Degasperi E; Paolucci S; Llaneras J; Vermehren J; Dultz G; Peiffer KH; Finkelmeier F; Herrmann E; Zeuzem S; Buti M; Lampertico P; Dietz J; Sarrazin C
JHEP Rep; 2024 Mar; 6(3):100994. PubMed ID: 38357421
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C.
Chen P; Jin M; Cao Y; Li H
Appl Health Econ Health Policy; 2021 May; 19(3):371-387. PubMed ID: 33210262
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus.
Da BL; Lourdusamy V; Kushner T; Dieterich D; Saberi B
Eur J Gastroenterol Hepatol; 2021 Jun; 33(6):859-861. PubMed ID: 32541241
[TBL] [Abstract][Full Text] [Related]
38. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
Poordad F; Felizarta F; Asatryan A; Sulkowski MS; Reindollar RW; Landis CS; Gordon SC; Flamm SL; Fried MW; Bernstein DE; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ
Hepatology; 2017 Aug; 66(2):389-397. PubMed ID: 28128852
[TBL] [Abstract][Full Text] [Related]
39. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan.
Liu CH; Liu CJ; Hung CC; Hsieh SM; Su TH; Sun HY; Tseng TC; Chen PJ; Chen DS; Kao JH
Liver Int; 2020 Apr; 40(4):758-768. PubMed ID: 31710759
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection.
Mei YY; Chen YM; Wu YK; Zhang XH; Xu WX
Can J Gastroenterol Hepatol; 2020; 2020():8872120. PubMed ID: 33194875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
